Literature DB >> 26498906

Mitigation of Insulin Resistance by Mangiferin in a Rat Model of Fructose-Induced Metabolic Syndrome Is Associated with Modulation of CD36 Redistribution in the Skeletal Muscle.

Liang Zhou1, Yongquan Pan1, Ritsu Chonan1, Robert Batey1, Xianglu Rong1, Johji Yamahara1, Jianwei Wang2, Yuhao Li2.   

Abstract

Mangiferin is one of the prominent active components responsible for the antidiabetic property of many traditional herbs, but its underlying mechanisms of action remain unclear. CD36 in skeletal muscle is known to contribute to the etiology of insulin resistance by facilitating fatty acid uptake. This study investigated the effect of mangiferin on insulin resistance. The results showed that treatment of Wistar-Kyoto rats with mangiferin (15 mg/kg, once daily, by oral gavage) for 7 weeks inhibited chronic liquid fructose consumption-induced increases in plasma insulin concentrations at the baseline and during oral glucose tolerance test (OGTT), and the homeostasis model assessment of insulin resistance index. It also suppressed the increases in fasted plasma nonesterified fatty acid (NEFA) concentration and the adipose tissue insulin resistance index. Mechanistically, mangiferin neither affected intakes of fructose and chow, and the increase in epididymal and perirenal fat, nor attenuated fructose-induced hypertension. In contrast, mangiferin attenuated fructose-induced acceleration of plasma NEFA clearance during OGTT, and tended to decrease excessive triglyceride accumulation in gastrocnemius. Immunofluorescence staining and subsequent rating of CD36-expressing fibers in gastrocnemius revealed that mangiferin restored fructose-stimulated sarcolemmal CD36 overexpression and decreased intracellular CD36 distribution. In addition, the effects of mangiferin on the parameters associated with insulin resistance and abnormal fatty acid metabolism were absent in the spontaneously hypertensive rats carrying numerous nonfunctional mutations in the CD36 gene. Thus, these results suggest that mangiferin treatment mitigates insulin resistance in a rat model of fructose-induced metabolic syndrome by modulating sarcolemmal and intracellular CD36 redistribution in the skeletal muscle.
Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26498906     DOI: 10.1124/jpet.115.229005

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  8 in total

Review 1.  Mangiferin modulation of metabolism and metabolic syndrome.

Authors:  Ekaterina Vladimirovna Fomenko; Yuling Chi
Journal:  Biofactors       Date:  2016-08-18       Impact factor: 6.113

2.  Treatment with Rhodiola crenulata root extract ameliorates insulin resistance in fructose-fed rats by modulating sarcolemmal and intracellular fatty acid translocase/CD36 redistribution in skeletal muscle.

Authors:  Ting Chen; Ling Yao; Dazhi Ke; Weiguo Cao; Guowei Zuo; Liang Zhou; Jian Jiang; Johji Yamahara; Yuhao Li; Jianwei Wang
Journal:  BMC Complement Altern Med       Date:  2016-07-12       Impact factor: 3.659

3.  Mangiferin Accelerates Glycolysis and Enhances Mitochondrial Bioenergetics.

Authors:  Zhongbo Liu; Pasha Apontes; Ekaterina V Fomenko; Nan Chi; Victor L Schuster; Irwin J Kurland; Jeffrey E Pessin; Yuling Chi
Journal:  Int J Mol Sci       Date:  2018-01-09       Impact factor: 5.923

Review 4.  High Dietary Fructose: Direct or Indirect Dangerous Factors Disturbing Tissue and Organ Functions.

Authors:  Dong-Mei Zhang; Rui-Qing Jiao; Ling-Dong Kong
Journal:  Nutrients       Date:  2017-03-29       Impact factor: 5.717

Review 5.  The Quest to Enhance the Efficacy of Berberine for Type-2 Diabetes and Associated Diseases: Physicochemical Modification Approaches.

Authors:  Solomon Habtemariam
Journal:  Biomedicines       Date:  2020-04-18

6.  Accelerated developmental adipogenesis programs adipose tissue dysfunction and cardiometabolic risk in offspring born to dams with metabolic dysfunction.

Authors:  Anna Mikolajczak; Nada A Sallam; Radha D Singh; Taylor B Scheidl; Emma J Walsh; Sebastian Larion; Carol Huang; Jennifer A Thompson
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-08-30       Impact factor: 4.310

7.  The Compound of Mangiferin-Berberine Salt Has Potent Activities in Modulating Lipid and Glucose Metabolisms in HepG2 Cells.

Authors:  Can Wang; Jian-Dong Jiang; Wei Wu; Wei-Jia Kong
Journal:  Biomed Res Int       Date:  2016-03-30       Impact factor: 3.411

8.  Pharmacokinetic and metabolomic analyses of Mangiferin calcium salt in rat models of type 2 diabetes and non-alcoholic fatty liver disease.

Authors:  He Lin; Houlei Teng; Wei Wu; Yong Li; Guangfu Lv; Xiaowei Huang; Wenhao Yan; Zhe Lin
Journal:  BMC Pharmacol Toxicol       Date:  2020-08-06       Impact factor: 2.483

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.